Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

NNC0165-1875

Stage Phase 2Stale

Sponsor Novo Nordisk A/S

Route injection

Sources

registry, as of 2019-09-06Stale

https://clinicaltrials.gov/study/NCT03707990

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 88. Conditions Obesity and Overweight. The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts. If participants take part in Part 1, they will either get a single dose of NNC0165-1875 o

ClinicalTrials.gov NCT03707990 protocol and results modules

registry, as of 2026-01-08Stale

https://clinicaltrials.gov/study/NCT04969939

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 120. Conditions Obesity. The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections pe

ClinicalTrials.gov NCT04969939 protocol and results modules

Studies

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Registry NCT03707990

Phase Phase 1

Status Completed

Enrollment 88

Start 2018-10-15

Primary completion 2019-08-13

Study completion 2019-08-13

NNC0165-1875

Comparator placebo

Population Obesity and Overweight

Placebo

Population Obesity and Overweight

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

Registry NCT04969939

Phase Phase 2

Status Completed

Enrollment 120

Start 2021-07-15

Primary completion 2022-12-06

Study completion 2023-01-30

Semaglutide 2.4 mg and NNC0165-1875 2.0 mg

Dose 2.4 mg and 2.0 mg

Regimen once weekly

Weeks 26

Comparator placebo

Population Obesity

Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg)

Dose 2.4 mg and 2.0 mg and 2.0 mg

Regimen once weekly

Weeks 26

Population Obesity

Semaglutide 2.4 mg and NNC0165-1875 1.0 mg

Dose 2.4 mg and 1.0 mg

Regimen once weekly

Weeks 26

Comparator placebo

Population Obesity

Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg)

Dose 2.4 mg and 1.0 mg and 1.0 mg

Regimen once weekly

Weeks 26

Population Obesity